ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.

Poornima Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.